Skip to main content

GreenLight PVP — Photoselective Vaporization of the Prostate

GreenLight Photoselective Vaporization of the Prostate (PVP) is an FDA-cleared 532 nm laser-based BPH therapy that vaporizes obstructive prostatic tissue with simultaneous hemostatic coagulation, making it the preferred surgical option for patients on antithrombotic therapy and a TURP-equivalent option for prostates ≤ 80 mL. The AUA 2023 Guideline Amendment gives PVP a Moderate Recommendation, Grade B for use with the 120 W or 180 W platforms.[1] For positioning vs other BPH options see BPH & Male LUTS — chooser.

Mechanism​

The GreenLight laser emits a 532 nm wavelength (green light) that is selectively absorbed by oxyhemoglobin but not by water. The result is rapid heating and vaporization of the highly vascular prostatic adenoma while sparing surrounding water-rich structures.[2][3] Tissue is converted to vapor and evacuated through the irrigant, creating an immediate cavity similar to TURP — but the laser simultaneously coagulates blood vessels at the resection surface, explaining the dramatically lower bleeding rates compared with electrocautery-based TURP.[3][4]

Device evolution​

GenerationPowerCrystalFiberKey advance
1st (PV / KTP)60–80 WPotassium-titanyl-phosphateSide-firingOriginal platform; smaller prostates
2nd (HPS)120 WLithium triborate (LBO)Side-firingHigher power, faster vaporization, larger prostates
3rd (XPS)180 WLBOMoXy fiber (liquid-cooled)Fastest vaporization; single-fiber procedures; broadest applicability

A meta-analysis of 8 studies comparing 180 W XPS to 120 W HPS found XPS had shorter operative time (MD 12.7 min, p = 0.0008), shorter lasing time (MD 10.1 min, p = 0.03), shorter catheterization (MD 0.43 d, p = 0.007), and lower overall complication rates (OR 1.52, p = 0.005), with no functional differences. XPS also achieved greater PSA reduction (MD −0.77, p = 0.003), suggesting more complete tissue removal.[5] A prospective comparison showed XPS required fewer fibers (1.0 vs 1.5) and saline bags (4.1 vs 7.0).[6]

Procedure​

Performed under general, spinal, or local anesthesia; typical OR time 45–90 min.[7][8]

  1. Standard cystoscope (22–26 Fr) into the prostatic urethra.
  2. Side-firing fiber advanced through the working channel.
  3. "Painting" sweep at near-contact distance, vaporizing layer by layer.
  4. Sequence: bladder neck distally to verumontanum, treating lateral lobes and median lobe as needed.
  5. Median lasing time 34 min (IQR 23–48); median total OR time 62 min (IQR 46–85).[7]
  6. Median energy 250 kJ (IQR 168–368); 92.6% of procedures completed with a single fiber.[7]
  7. Catheter removal POD 1 in 60.1%; median catheterization 2 d.[7]
  8. Most patients discharged within 24 h — many same-day.

Patient selection​

  • Moderate-to-severe LUTS (IPSS ≥ 12–13).
  • Optimal volume ≤ 80 mL. Use beyond 80 mL is feasible but with higher retreatment rates.[1][8]
  • Antithrombotic therapy is the strongest niche — multiple studies confirm safety on warfarin, aspirin, clopidogrel, and even dual / triple antithrombotic therapy without discontinuation.[9][10][11]
  • Treats obstructive median lobes.
  • Suitable for high-ASA-class patients who may not tolerate TURP.
  • PVR < 250 mL.

Clinical efficacy — TURP equivalence (GOLIATH)​

The GOLIATH trial is the pivotal RCT supporting PVP. 281 men randomized to 180 W XPS PVP vs TURP at 9 European centers.[12][13][14]

  • Noninferiority of XPS to TURP for IPSS, Qmax, and complication-free proportion at 6, 12, and 24 months.
  • IPSS, Qmax, prostate volume, and PSA reductions not statistically different at any timepoint.
  • 24-month complication-free rate 83.6% (XPS) vs 78.9% (TURP).
  • XPS had shorter catheterization, shorter LOS, and faster return to stable health.
  • Early reintervention within 30 days 3× higher after TURP (p = 0.025).[13]
  • Overall reintervention rates comparable at 24 months.

SR / meta-analysis (22 studies, n = 2,665 PVP vs TURP)​

No significant difference in IPSS, Qmax, QoL, PVR, or IIEF at 3, 24, 36, or 60 months. PVP had significantly lower blood loss, transfusion, clot retention, TUR syndrome, capsular perforation, catheterization time, and hospitalization (all p < 0.05).[15] A 13-RCT meta-analysis confirmed lower transfusion (RR 0.20, p < 0.001), clot retention (RR 0.12, p < 0.001), and TUR syndrome (RR 0.17, p = 0.002), with 34% lower sexual dysfunction (RR 0.66, p = 0.04).[16] Procedure time was ~ 10 min longer with GreenLight.[16]

Global GreenLight Group — large international experience​

The Global GreenLight Group cohort (XPS, expert centers) reported[7]:

  • Median prostate volume 64 mL (range 19–301).
  • 30-day all-cause mortality 0.3%.
  • Median catheterization 2 d, hospitalization 1 d.
  • Significant IPSS / QoL / Qmax / PVR improvements at 3 mo with sustained improvement through 60 mo.
  • PSA reduction 43.9% at 3 mo and 46.4% at 60 mo.

Long-term outcomes (5–10 yr)​

  • 120 W HPS, 5-yr (n = 159): success 82.1% / 80.8% / 76.1% at 1 / 3 / 5 yr; reoperation 3.1% repeat PVP, 1.2% BNC / stricture.[17]
  • 80 W KTP vs TURP, 5-yr RCT: equivalent IPSS / PVR / Qmax improvements; retreatment 14.3% vs 11.9% (p = 0.9).[18]
  • 10-yr follow-up (n = 1,154, 80 / 120 W): IPSS / QoL / PSA significantly improved at 10 yr; Qmax / PVR not significantly improved at 10 yr; retreatment-free survival 93.9% at 5 yr / 79.0% at 10 yr.[19]
  • 80 W KTP, 5-yr (n = 246): AUA score improved 79%, Qmax improved 172%, retreatment 8.9%.[20]

Retreatment and durability​

SettingVolumeFollow-upRetreatment
Global GreenLight Group (XPS, expert)64 mLvariable1.5%[7]
120 W HPS, 5-yr100 mL5 yr3.1% repeat PVP[17]
80 W KTP, 5-yr55 mL mean5 yr8.9%[20]
80 W KTP vs TURP RCTmixed5 yr14.3% vs 11.9%[18]
XPS, very large (> 100 mL)121 mL median3 yr9.3%[21]
3-arm RCT PVP vs TURP vs HoLEP (80–150 mL)105 mL mean3 yr27% PVP[22]
Single-center, 3 laser modelsmixed61 mo13.8% overall[23]
10-yr follow-upmixed10 yr21% (retreatment-free 79%)[19]

Key takeaway: retreatment is low (1.5–9%) for prostates ≤ 80–100 mL but reaches 27% at 3 yr for prostates 80–150 mL — for which enucleation techniques (HoLEP, GreenLEP) are preferred.[1][22] Predictors of retreatment include lower energy density (< 4 kJ/mL), larger prostate volume, lower-power platform, and inadequate vaporization technique.[24][8]

Safety profile​

PVP has a superior perioperative safety profile compared with TURP — particularly bleeding[15][16]:

  • No TUR syndrome (saline irrigation).
  • Transfusion rate 0–0.26× that of TURP across all meta-analyses.
  • Clot retention 88% lower than TURP.
  • Common AEs: dysuria (most common; often 2–6 wk), urgency, UTI, hematuria.
  • Bladder-neck contracture 3.4–7.7%; urethral stricture 2.1–5.6% — comparable to TURP.[24][25]
  • 30-day all-cause mortality 0.3% in the Global GreenLight Group.[7]
  • Clavien-Dindo Grade III–V comparable between PVP and TURP.[16]

Antithrombotic safety — PVP's signature niche​

  • Lee 2016 (n = 384; 38% aspirin, 9% clopidogrel, 15% warfarin, 2% triple therapy): no significant differences in complications, UTI, retention, stricture, or reoperation between anticoagulated and non-anticoagulated patients.[9]
  • Meskawi 2019 (n = 274 high-risk CV patients on antithrombotic therapy): serious bleeding events rare and equivalent to non-high-risk patients; minor hematuria and readmission rates higher.[10]
  • Chung 2011 (n = 162 systemic anticoagulation including warfarin / aspirin / clopidogrel and combinations): mean hematocrit decrease only 1.94%; 4% delayed bleeding; 2% transfusion.[11]
  • A focused review concluded PVP was not associated with serious bleeding events requiring transfusion in patients on anticoagulation or antiplatelet therapy.[3]

Sexual function​

PVP sexual-function data are more heterogeneous than UroLift / Aquablation / iTIND.

  • 13-RCT meta-analysis: sexual dysfunction 34% lower vs TURP (RR 0.66, p = 0.04).[16]
  • 22-study SR / meta: no significant IIEF difference vs TURP at 3 / 24 / 36 / 60 mo.[15]
  • A focused SR noted a trend toward decline in erectile function in men with sustained preoperative erection; data heterogeneous.[4]
  • Retrograde ejaculation is the most common sexual side effect. In large prostates (> 80 g), antegrade ejaculation preserved in only 26.9% standard PVP vs 1.2% GreenLEP.[26]

Ejaculatory hood–sparing PVP​

A modified technique preserves the paracollicular and supracollicular tissue proximal to the verumontanum.

  • Abolazm 2020 RCT double-blinded: antegrade ejaculation preserved in 85% (hood-sparing) vs 31.6% (standard PVP) (p = 0.001), with comparable urodynamic relief.[27]
  • Brant 2020: 80% antegrade-ejaculation preservation with improved overall sexual-function scores.[28]

GreenLEP — laser enucleation extension​

GreenLEP combines vaporization with en-bloc enucleation using the 180 W XPS laser, extending PVP's applicability to large prostates > 80 mL.

  • Wang 2025 SR / meta of 13 studies: GreenLEP had superior energy efficiency, better Qmax / PVR / PSA, and the lowest reoperation rate vs standard PVP and anatomical PVP (OR 27.30 favoring lower reoperation, p < 0.001).[29]
  • Misrai 2016 direct comparison GreenLEP vs PVP for prostates > 80 mL: GreenLEP had shorter OR time (60 vs 82 min, p < 0.001) and better functional outcomes.[30]
  • 3-arm RCT 80–150 mL GreenLEP vs HoLEP vs TURP (Elshal 2020): GreenLEP higher retreatment than HoLEP (6.7% vs 0% at 3 yr, p = 0.04) and longer OR time.[22]
  • GreenLEP serves as a bridge technique for urologists experienced with PVP who wish to adopt enucleation without HoLEP's steep learning curve.[31]

Comparison with other BPH options​

ProcedureVolume rangeAnticoagulation5-yr retreatmentSexual preservation
GreenLight PVP≤ 80 mL optimal; ≤ 100 with caveatsBest — safe on warfarin / DAPT / triple1.5–9% (≤ 80 mL); 27% at 3 yr (80–150 mL)RE common; hood-sparing improves to ~ 80–85% antegrade
TURPup to 80 mLHoldLowest of all optionsRE 60–75%; ED ~ 14%
HoLEPAny sizePossible with experience1–2%RE 18–23%; SUI 5–9.3%
Aquablation30–150+ mLGeneral / regional~ 4%Antegrade preservation 72–99.6%
Optilume BPH20–80 mLOffice-basednot yet 5-yrExcellent erectile / ejaculatory
Rezūm30–80 mLOffice-based4.4%Excellent
UroLift≤ 80 mL (≤ 100 RW)Safe on anticoagulation~ 22% (real-world)Best — 0% anejaculation in pooled MIST
iTIND25–75 mLOffice-basedHigh per Italian DelphiBest alongside UroLift (~ 1% anejaculation)

Where GreenLight PVP fits​

Distinguishing advantages​

  • Gold standard for anticoagulated patients — performable without holding warfarin / DAPT / triple antithrombotic therapy.
  • Excellent hemostasis — lowest bleeding rates of any resective / ablative BPH procedure.
  • Short catheterization (1–2 d) and short LOS (often same-day or next-day).
  • TURP-equivalent efficacy for prostates ≤ 80 mL (GOLIATH 24-mo noninferiority).
  • Lower hospital-stay cost than TURP, partially offsetting fiber consumable cost.

Principal limitations​

  • No tissue specimen for pathology — important when occult prostate-cancer detection is desired (note: incidental prostate cancer rate at TURP is ~ 4–8%).
  • Higher retreatment rates for large prostates (> 80–100 mL) compared with enucleation (Elshal 2020 — 27% at 3 yr in 80–150 mL).
  • Retrograde ejaculation rates similar to TURP with standard technique (~ 70–75%); ejaculatory hood-sparing PVP reduces this to ~ 15–20%.[27]
  • Longer procedure time than TURP (~ 10 min longer).[16]
  • Consumable costs (laser fibers) significant; partially offset by shorter LOS.
  • Requires general or regional anesthesia (not office-based).

See also​

BPH & Male LUTS — chooser · Prostate Enucleation / HoLEP · Aquablation · Rezūm · Optilume BPH · UroLift PUL · iTIND · Simple Prostatectomy · Prostate Artery Embolization

References​

1. Sandhu JS, Bixler BR, Dahm P, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2024;211(1):11-19. doi:10.1097/JU.0000000000003698

2. Chughtai B, Te A. Photoselective vaporization of the prostate for treating benign prostatic hyperplasia. Expert Rev Med Devices. 2011;8(5):591-595. doi:10.1586/erd.11.25

3. Schwartz RN, Couture F, Sadri I, et al. Reasons to believe in vaporization: a review of the benefits of photo-selective and transurethral vaporization. World J Urol. 2021;39(7):2263-2268. doi:10.1007/s00345-020-03447-x

4. Rieken M, Bachmann A. Update on GreenLight laser vaporization (PVP) 2014. World J Urol. 2015;33(4):531-537. doi:10.1007/s00345-014-1437-8

5. Wang M, Xi Y, Qiu Z, et al. Comparative efficacy and safety of 180 W XPS vs. 120 W HPS GreenLight laser therapy for benign prostatic hyperplasia: a systematic review and meta-analysis. PeerJ. 2024;12:e18615. doi:10.7717/peerj.18615

6. Ben-Zvi T, Hueber PA, Liberman D, Valdivieso R, Zorn KC. GreenLight XPS 180 W vs HPS 120 W laser therapy for benign prostate hyperplasia: a prospective comparative analysis after 200 cases in a single-center study. Urology. 2013;81(4):853-858. doi:10.1016/j.urology.2012.12.031

7. Law KW, Tholomier C, Nguyen DD, et al. Global GreenLight Group: largest international GreenLight experience for benign prostatic hyperplasia to assess efficacy and safety. World J Urol. 2021;39(12):4389-4395. doi:10.1007/s00345-021-03688-4

8. Meskawi M, Hueber PA, Valdivieso R, et al. Multicenter international experience of 532 nm-laser photo-vaporization with GreenLight XPS in men with large prostates (prostate volume > 100 cc). World J Urol. 2017;35(10):1603-1609. doi:10.1007/s00345-017-2007-7

9. Lee DJ, Rieken M, Halpern J, et al. Laser vaporization of the prostate with the 180-W XPS-GreenLight laser in patients with ongoing platelet aggregation inhibition and oral anticoagulation. Urology. 2016;91:167-173. doi:10.1016/j.urology.2016.01.021

10. Meskawi M, Hueber PA, Valdivieso R, et al. Complications and functional outcomes of high-risk patient with cardiovascular disease on antithrombotic medication treated with the 532-nm laser photo-vaporization GreenLight XPS-180 W for benign prostate hyperplasia. World J Urol. 2019;37(8):1671-1678. doi:10.1007/s00345-018-2560-8

11. Chung DE, Wysock JS, Lee RK, et al. Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia. J Urol. 2011;186(3):977-981. doi:10.1016/j.juro.2011.04.068

12. Bachmann A, Tubaro A, Barber N, et al. 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European multicentre randomised trial — the GOLIATH study. Eur Urol. 2014;65(5):931-942. doi:10.1016/j.eururo.2013.10.040

13. Bachmann A, Tubaro A, Barber N, et al. A European multicenter randomized noninferiority trial comparing 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the treatment of benign prostatic obstruction: 12-month results of the GOLIATH study. J Urol. 2015;193(2):570-578. doi:10.1016/j.juro.2014.09.001

14. Thomas JA, Tubaro A, Barber N, et al. A multicenter randomized noninferiority trial comparing GreenLight-XPS laser vaporization of the prostate and transurethral resection of the prostate for the treatment of benign prostatic obstruction: two-yr outcomes of the GOLIATH study. Eur Urol. 2016;69(1):94-102. doi:10.1016/j.eururo.2015.07.054

15. Lai S, Peng P, Diao T, et al. Comparison of photoselective green light laser vaporisation versus traditional transurethral resection for benign prostate hyperplasia: an updated systematic review and meta-analysis of randomised controlled trials and prospective studies. BMJ Open. 2019;9(8):e028855. doi:10.1136/bmjopen-2018-028855

16. Gill BC, Miller LE, Bhattacharyya S, Cash H, Eure GR. Complications of GreenLight laser vs transurethral resection of the prostate for treatment of lower urinary tract symptoms: meta-analysis of randomized trials. Urology. 2024;184:259-265. doi:10.1016/j.urology.2023.12.018

17. Park J, Cho SY, Cho MC, Jeong H, Son H. 5-year long-term efficacy of 120-W GreenLight photoselective vaporization of the prostate for benign prostate hyperplasia. PLoS One. 2017;12(9):e0184442. doi:10.1371/journal.pone.0184442

18. Mordasini L, Di Bona C, Klein J, et al. 80-W GreenLight laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic obstruction: 5-year outcomes of a single-center prospective randomized trial. Urology. 2018;116:144-149. doi:10.1016/j.urology.2018.01.037

19. Yamada Y, Furusawa J, Sugimura Y, Kuromatsu I. Photoselective vaporization of the prostate: long-term outcomes and safety during 10 years of follow-up. J Endourol. 2016;30(12):1306-1311. doi:10.1089/end.2016.0522

20. Hai MA. Photoselective vaporization of prostate: five-year outcomes of entire clinic patient population. Urology. 2009;73(4):807-810. doi:10.1016/j.urology.2008.08.502

21. Meskawi M, Hueber PA, Valdivieso R, et al. Multicenter international experience of 532 nm-laser photo-vaporization with GreenLight XPS in men with large prostates > 100 cc. World J Urol. 2017;35(10):1603-1609. doi:10.1007/s00345-017-2007-7

22. Elshal AM, Soltan M, El-Tabey NA, Laymon M, Nabeeh A. Randomised trial of bipolar resection vs holmium laser enucleation vs GreenLight laser vapo-enucleation of the prostate for treatment of large benign prostate obstruction: 3-years outcomes. BJU Int. 2020;126(6):731-738. doi:10.1111/bju.15161

23. Özveren B, Karşıyakalı N, Türkeri L. Surgical reintervention requirements following GreenLight PVP: a single-center experience using three different laser device models. Arab J Urol. 2024;22(1):31-38. doi:10.1080/2090598X.2023.2222262

24. Elshal AM, Elmansy HM, Elhilali MM. Can we predict the outcome of 532 nm laser photoselective vaporization of the prostate? Time to event analysis. J Urol. 2012;188(5):1746-1753. doi:10.1016/j.juro.2012.07.030

25. Ruszat R, Seitz M, Wyler SF, et al. GreenLight laser vaporization of the prostate: single-center experience and long-term results after 500 procedures. Eur Urol. 2008;54(4):893-901. doi:10.1016/j.eururo.2008.04.053

26. Huet R, Peyronnet B, Khene ZE, et al. Prospective assessment of the sexual function after GreenLight endoscopic enucleation and GreenLight 180 W XPS photoselective vaporization of the prostate. Urology. 2019;131:184-189. doi:10.1016/j.urology.2019.06.020

27. Abolazm AE, El-Hefnawy AS, Laymon M, Shehab-El-Din AB, Elshal AM. Ejaculatory hood sparing versus standard laser photoselective vaporization of the prostate: sexual and urodynamic assessment through a double-blinded, randomized trial. J Urol. 2020;203(4):792-801. doi:10.1097/JU.0000000000000685

28. Brant A, Cho A, Posada Calderon L, et al. Ejaculatory hood-sparing vaporization of the prostate and its impact on erectile, ejaculatory, and sexual function. Urology. 2020;144:177-181. doi:10.1016/j.urology.2020.06.072

29. Wang M, Chen S, Xi Y, et al. Comparative efficacy and safety of GreenLight laser vaporization, anatomical vaporization, and enucleation for benign prostatic hyperplasia: a systematic review and meta-analysis. Lasers Med Sci. 2025;40(1):139. doi:10.1007/s10103-025-04389-9

30. Misrai V, Kerever S, Phe V, et al. Direct comparison of GreenLight laser XPS photoselective prostate vaporization and GreenLight laser en bloc enucleation of the prostate in enlarged glands > 80 mL: a study of 120 patients. J Urol. 2016;195(4 Pt 1):1027-1032. doi:10.1016/j.juro.2015.10.080

31. Bajic P, Noriega N, Gorbonos A, Karpman E. GreenLight laser enucleation of the prostate (GreenLEP): initial experience with a simplified technique. Urology. 2019;131:250-254. doi:10.1016/j.urology.2019.06.018